Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Athersys, Inc.    ATHX

ATHERSYS, INC. (ATHX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Athersys, Inc. : Analysis Reports On Active NASDAQ Stocks: (NASDAQ: ATHX), (NASDAQ: PDLI)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/18/2013 | 07:40am CEST

New York (April 18th, 2013) - Athersys, Inc. (NASDAQ: ATHX) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Athersys' application to expand its ongoing Phase 2 study evaluating the administration of MultiStem(R) therapy to patients who have suffered an ischemic stroke. Enrollment at United Kingdom sites is expected to commence following final Ethics Committee review and the completion of final preparations at participating clinical centers.

"The MHRA authorization will enable us to bring several leading United Kingdom stroke centers into the study, which will help us to speed the completion of the stroke clinical trial," said Dr. Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys. "The authorization is also noteworthy as it marks the initiation of MultiStem clinical development activity in the United Kingdom."

Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine.

Get everything traders and investors are looking for when trading ATHX here:

http://stockreportdaily.com/market-scan/?symbol=ATHX


PDL BioPharma Inc. (NASDAQ:PDLI) traded at $ 7.45 in the last session, which is 0.00 (0.00%). The stock has a Range of 7.31 - 7.46. The stock has a 52 week low and high of 6.09 - 8.43 respectively. The stock has a Market Cap of 1.04B. The stock traded a volume of 1.66M. The stock has a 30 day average volume of 1.81M.

In trading on Wednesday, shares of PDL BioPharmaInc (PDLI) crossed below their 200 day moving average of $7.32, changing hands as low as $7.31 per share.

PDL BioPharma, Inc. (PDL) is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014.

Find out more on PDLI here:

http://stockreportdaily.com/market-scan/?symbol=PDLI

ABOUT US:

Stockreportdaily.com issues momentum alerts on stocks that can provide gains to day traders. Stockreportdaily.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. Stockreportdaily.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Stockreportdaily.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the Stockreportdaily.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www. Stockreportdaily.com

Disclosure: Stockreportdaily.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Stockreportdaily.com website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit; http://www.Stockreportdaily.com/disclaimer/

Contact Info:
George Fitz
Stock Report Daily
[email protected]
347-905-5009


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ATHERSYS, INC.
06/20ATHERSYS, INC / NEW : Submission of Matters to a Vote of Security Holders (form ..
AQ
06/11MONDAY SECTOR LAGGARDS : Biotechnology, General Contractors & Builders
AQ
06/08ATHERSYS, INC / NEW : Entry into a Material Definitive Agreement (form 8-K)
AQ
06/07ATHERSYS : Healios receives rights to develop and commercialize additional indic..
PU
06/07ATHERSYS : Announces Expansion of Collaboration With Healios
GL
06/07ATHERSYS : Announces Expansion of Collaboration With Healios
AQ
06/05ATHERSYS, INC / NEW : Regulation FD Disclosure (form 8-K)
AQ
06/01ATHERSYS, INC / NEW : Amendments to Articles of Inc. or Bylaws; Change in Fiscal..
AQ
06/01ATHERSYS, INC / NEW : Regulation FD Disclosure (form 8-K)
AQ
05/10ATHERSYS : NEW Management's Discussion and Analysis of Financial Condition and R..
AQ
More news
News from SeekingAlpha
06/11Midday Gainers / Losers (06/11/2018) 
06/11HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (06/11/2018) 
06/07PREMARKET GAINERS AS OF 9 : 05 am (06/07/2018) 
06/07Athersys expands collaboration with Healios; shares ahead 16% premarket 
05/24Trauma Trial Boosts Athersys's Allure 
Financials ($)
Sales 2018 15,2 M
EBIT 2018 -31,0 M
Net income 2018 -30,6 M
Finance 2018 2,60 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 18,5x
Capi. / Sales 2019 57,5x
Capitalization 284 M
Chart ATHERSYS, INC.
Duration : Period :
Athersys, Inc. Technical Analysis Chart | ATHX | US04744L1061 | 4-Traders
Technical analysis trends ATHERSYS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 7,33 $
Spread / Average Target 263%
EPS Revisions
Managers
NameTitle
Gil van Bokkelen Chairman & Chief Executive Officer
William B. J. Lehmann President, Chief Operating Officer & Secretary
Laura K. Campbell Principal Accounting Officer & SVP-Finance
John J. Harrington Director, Chief Scientific Officer & Executive VP
Rakesh Ramachandran VP-Information Technology & Communications
Sector and Competitors
1st jan.Capitalization (M$)
ATHERSYS, INC.11.60%284
GILEAD SCIENCES-0.98%92 241
VERTEX PHARMACEUTICALS3.10%39 371
REGENERON PHARMACEUTICALS-13.00%34 653
SAREPTA THERAPEUTICS INC176.22%9 432
NEUROCRINE BIOSCIENCES, INC.32.39%9 234